DANYELZA
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for DANYELZA, covering 2020-11-25 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 [Phase 2]